Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Orthofix Medical Inc. (NASDAQ:OFIX) today announced that President and Chief Executive Officer Jon Serbousek will present at the Bank of America Securities 2020 Healthcare Virtual Conference on Thursday, May 14, 2020 at 1:00 p.m. ET.
Orthofix (OFIX) delivered earnings and revenue surprises of -18.18% and 0.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Joining me on the call today are President and Chief Executive Officer, Jon Serbousek; and Chief Financial Officer, Doug Rice. During this call, we'll be making forward-looking statements that involve risks and uncertainties.
Investors who take an interest in Orthofix Medical Inc. (NASDAQ:OFIX) should definitely note that the Independent...
Today we will run through one way of estimating the intrinsic value of Orthofix Medical Inc. (NASDAQ:OFIX) by...
Orthofix Medical completes the acquisition of the FITBONE intramedullary lengthening system for limb lengthening of the femur and tibia bones.
Orthofix (OFIX) pledges support for the continuation of the FDA's Class III status of BGS devices.
Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the first quarter ended March 31, 2020. Net sales were $104.8 million, diluted earnings per share ("EPS") was $1.32 and adjusted EPS was $0.09.
Orthofix (OFIX) delivered earnings and revenue surprises of 0.00% and -1.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, May 06, 2020 -- Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Orthofix Medical Inc..
Orthofix Medical Inc., a global medical device company, today announced its sponsorship of Olympic Gold Medalist and Spine Patient Laura Wilkinson.
Orthofix today announced preliminary financial results for the first quarter ended March 31, 2020 and provided a business update.
We are upbeat about the year-over-year revenue growth recorded by majority of Orthofix's (OFIX) key operating segments in Q4.
Orthofix Medical Inc. (NASDAQ:OFIX) shareholders (or potential shareholders) will be happy to see that the Independent...
Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that it plans to release financial results for the first quarter 2020 before market open on Friday, May 8, 2020. Jon Serbousek, President and Chief Executive Officer, and Doug Rice, Chief Financial Officer, will host a conference call and webcast to review the Company’s results at 8:30 a.m. ET the same day.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 29) Cabaletta Bio Inc (NASDAQ: CABA ) Edwards Lifesciences ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm ...
Shares of Orthofix Medical (NASDAQ:OFIX) remained unaffected at $36.16 after the company reported Q1 results.Quarterly Results Earnings per share fell 66.67% over the past year to $0.09, which beat the estimate of $0.06.Revenue of $104,823,000 lower by 3.93% year over year, which missed the estimate of $105,860,000.Looking Ahead Orthofix Medical hasn't issued any earnings guidance for the time being.Orthofix Medical hasn't issued any revenue guidance for the time being.Conference Call Details Date: May 08, 2020View more earnings on OFIXWebcast URL: https://edge.media-server.com/mmc/p/qc9jp9anPrice Action 52-week high: $57.40Company's 52-week low was at $22.11Price action over last quarter: down 1.47%Company Description Orthofix Medical Inc is a medical device company that provides reconstructive and regenerative orthopedic and spine solutions to physicians. The company has four reportable segments include Bone Growth Therapies, Spinal Implants, Biologics, and Orthofix Extremities. It generates maximum revenue from Bone Growth Therapies segment. Geographically, it generates maximum revenue from a company the U.S and also has a presence in Italy, Germany, United Kingdom, Brazil, and other countries.See more from Benzinga * Harsco: Q1 Earnings Insights * Recap: Mersana Therapeutics Q1 Earnings * Noble Midstream Partners: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]